Doctor of Pharmacy with a master’s degree in management and pharmaceutical marketing, Judith Greciet spent some fifteen years working her way up through subsidiaries of international pharmaceutical companies. She has held major managerial positions with increasing operational and strategic responsibilities from leading sales teams, heading marketing and strategy departments (Pharmacia, Zeneca, LFB, Wyeth France (now Pfizer)) until she finally became President of the French subsidiary of the Japanese laboratory Eisai in June 2007. Throughout her career, Judith Greciet has cultivated a keen awareness of the marketing and business environment of drugs, in France in particular and more broadly in Europe, as well as confronting market access issues, particularly in the areas of oncology and immunology with innovative products such as Enbrel (rheumatology).

Appointed Chief Executive Officer of Onxeo in 2011 (BioAlliance Pharma until 2014), Judith Greciet pursued development of the company by remoulding the strategy towards new growth-areas such as oncology.

Her mandate was renewed for 3 years at the annual shareholders’ general meeting of 2017.

He began his career as Deputy Chief Financial Officer at Total in Cameroon in 1990 and then as Financial Auditor at Ernst & Young on various missions in the industrial and financial sectors.

He then moved to the pharmaceutical industry where, from 1996 to 2006, he held positions of increasing responsibility within the finance division of Pfizer France: first in charge of the treasury and internal audit as Director of Treasury, Tax and Audit. In this position, he was responsible in particular for financial risk management for the French subsidiaries of Pfizer and he managed the financial implementation of various restructuring operations (including two mergers, one with Warner-Lambert in 2000 and then Pharmacia in 2003) as well as the implementation of tax and financial optimisation schemes.
Nicolas Fellmann is a graduate of Lyon Graduate School of Management (EM Lyon).

Since 2005, Olivier de Beaumont was with Stallergenes Greer as Senior Vice President, Head of Global Clinical Development, Pharmacovigilance and Medical Affairs, and a member of the Executive Committee. Prior to that, he led various clinical development programs and strategic marketing activities at Quintiles and Aventis, addressing a wide range of therapeutic areas and leading teams, notably in oncology. Dr. de Beaumont is a medical doctor and also holds a MBA from ESCP Business School and a Masters degree in Public Health & Health Economics.

Audrey Legentil-Duméry worked as a Senior HR consultant with a Paris-based agency, managing HR on behalf of diverse companies, notably accompanying SME’s through periods of growth and transition.

Ms. Legentil-Duméry successfully conducted several missions in the pharma and biotech sectors.

Audrey Legentil-Duméry holds a Magister and a Master in Management and Intercultural Communication from CELSA (Sorbonne, Paris).